Personalis Has Struggled Since Its IPO - Here's How I'd Play It
The company has a collaboration with Merck, and there are far worse partners you could have when working in the cancer segment of biotech.
GlaxoSmithKline Could Trade Up to the $75 Area in the Months Ahead
Let's see what we might expect.
Bristol-Myers Squibb May Trade Sideways for a Bit but Expect New Highs Later
The drugmaker's shares are up about 50% since last July and could use a rest, but are likely to move higher longer term.
Emergent BioSolutions Appears on a Healthy Trajectory
Investors may consider dosing up on the long side of this vaccine provider.
3 Boomer-Inspired Drug Plays With Dividend Appeal
Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.
Lock in Profits on InMode Before They Slip Away
Let's check out two charts.
Johnson & Johnson Finally Shakes Off Its Bad News 'Overhang'
It looks like JNJ has its swagger back.
Let's See How These Three Dividend Aristocrats Stack Up
Two food-related names and one in health care look like promising investments right now.
Cooper Cos. Can Rally Further After Some Sideways Consolidation
Time to review the charts and indicators.
This Dividend Stock Is Tipping the Scales for Investors
As more Americans struggle with obesity, Medifast sees strength in weight-loss offerings.